Interestingly, a humanized CCL24-neutralizing monoclonal antibody, CM101, was shown to significantly mitigate liver fibrosis and inflammation in preclinical models of NASH and primary sclerosing cholangitis (Segal-Salto et al., 2020; Greenman et al., 2023). Here, CCL24 is linked to metabolic dysfunction-associated steatohepatitis.